Blood bank aims to predict leukemia risk in MDS patients
NCT ID NCT04869683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gathers blood and bone marrow samples from 150 adults with myelodysplastic syndrome (MDS), a blood disorder that can turn into acute leukemia. Researchers want to find biological markers that help predict which patients are likely to progress to leukemia. The goal is to better understand the disease and improve future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which patients with myelodysplastic syndrome are at higher risk of developing acute leukemia, leading to earlier monitoring or treatment.
- What could go wrong
- This is an observational study that collects samples for future research, not a treatment trial. It may not directly lead to new therapies or change patient care in the short term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH MULTILINEAGE DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Brest
RECRUITINGBrest, 29609, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?